Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-04-16

Development of human endothelial cellines with preserved morphological and functional characteristics utilisation in toxicological and pharmacological tests

Objectif

The objective of the current proposal is to produce stable, immortalized lines of human endothelial cells, safe for use, which retain their functional properties and have been fully evaluated for pharmacological and toxicological testing. This objective will require innovative strategies for "minimal immortalization" where metabolic disruption induced by the immortalizing gene product is engineered down to a minimum.
The endothelium constitutes the internal lining of the circulatory system and plays a pivotal role in the maintenance of the vessel wall integrity. The alteration of the functional properties of endothelial cells is the first step in the development of cardiovascular diseases such as astherosclerosis and myocardinal infarction. The possibility to isolate and study these cells invitro is limited by their short life span. This work concerns the possibility to immortalize cultured human endothelial cells by inserting specific oncogenes.

The first objectives of this work include immortalization of endothelial cells with retroviral vectors; construction of new viral vectors; and establishment of functional assay system for endothelial cells.

Results achieved to date are:
two human endothelial cell lines transfected with retroviral constructs and two distinct oncogenes have been developed and have been characterized for specific markers and for morphological parameters; plasmid vectors have been prepared; functional assays for evaluating a series of functional activities of endothelial cells have been set up; assays for the screening of substances with potential toxicology effects have been established.
Human endothelial cells (HEC) in culture are a vital cellular model in the study of vascular diseases. The development of HEC lines retaining their differentiated characteristics would prove an invaluable tool for pharmacological and toxicological studies. Previous attempts have resulted in HEC lines either with substantially altered properties or, when amphotropic pseudotypes of murine sarcoma virus were used, not fully safe in terms of infection of the workers. The current proposal describes innovative molecular biology strategies that will be used to test the effect of a series of genes with the potential to immortalize/transform cells. Three different approaches will be followed. The first two will use either retroviral or EBV vectors which will allow efficient introduction of the gene of interest into HEC and provide a screening method for a variety of oncogenes, growth factor genes and receptor genes. The third approach will use integrative
plasmids which will allow the manipulation of gene expression using heterologous promoters to achieve 'minimal immortalization' i.e. where metabolic disruption induced by the immortalizing gene product is engineered down to a mimimum. The HEC lines will be then characterized for their growth characteristics and specific endothelial markers. In addition a full pharmacological and toxicological assessment of the HEC lines' responses will be performed.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: Le vocabulaire scientifique européen.

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

Programmes de financement pluriannuels qui définissent les priorités de l’UE en matière de recherche et d’innovation.

Thème(s)

Les appels à propositions sont divisés en thèmes. Un thème définit un sujet ou un domaine spécifique dans le cadre duquel les candidats peuvent soumettre des propositions. La description d’un thème comprend sa portée spécifique et l’impact attendu du projet financé.

Données non disponibles

Appel à propositions

Procédure par laquelle les candidats sont invités à soumettre des propositions de projet en vue de bénéficier d’un financement de l’UE.

Données non disponibles

Régime de financement

Régime de financement (ou «type d’action») à l’intérieur d’un programme présentant des caractéristiques communes. Le régime de financement précise le champ d’application de ce qui est financé, le taux de remboursement, les critères d’évaluation spécifiques pour bénéficier du financement et les formes simplifiées de couverture des coûts, telles que les montants forfaitaires.

CSC - Cost-sharing contracts

Coordinateur

MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH
Contribution de l’UE
Aucune donnée
Coût total

Les coûts totaux encourus par l’organisation concernée pour participer au projet, y compris les coûts directs et indirects. Ce montant est un sous-ensemble du budget global du projet.

Aucune donnée

Participants (2)

Mon livret 0 0